Epidemiologic Investigation
On October 24, 2007, MDPH identified a listeriosis isolate (from patient 3) with a PFGE pattern indistinguishable from an isolate (from patient 1) submitted approximately 120 days earlier (Table) . The PFGE patterns associated with these patients had never been observed before in Massachusetts or in PulseNet (the national molecular subtyping network for foodborne disease surveillance). A review of available information on these two patients did not indicate a common exposure. On November 20, MDPH identified a third case (in patient 4) with an indistinguishable PFGE pattern. Attempts were made to interview this patient but were unsuccessful. On November 27, a fourth case (in patient 5) was reported to MDPH and, in the course of investigating that case, samples of coffeeflavored milk produced by dairy A were collected on November 29 from the patient's home for testing. In early December, MDPH determined that the clinical isolate from patient 5 had PFGE patterns indistinguishable from those of patients 1, 3, and 4. An epidemiologic investigation of patient 5 indicated exposure to milk produced by dairy A. On December 21, a L. monocytogenes isolate obtained from the milk sample taken from the home of patient 5 was confirmed to have a PFGE pattern indistinguishable from that of the isolates from the four identified listeriosis patients. MDPH then investigated all 11 cases of listeriosis reported during 2007 in Massachusetts residents for whom no clinical isolates had been submitted to the State Laboratory Institute (SLI) of MDPH for PFGE analysis. The purpose of the investigation was to determine if any patients had exposure to milk products produced by dairy A during the 6 weeks preceding their illness. Telephone interviews were conducted with patients or next of kin. During this retrospective investigation, patient 2 was identified.
A case of outbreak-associated listeriosis was defined as illness in a Massachusetts resident with illness onset in 2007 who 1) was culture-positive for L. monocytogenes with PFGE patterns that matched the outbreak patterns generated with AscI and ApaI restriction enzymes (as established by the first case) or 2) had culture-confirmed L. monocytogenes and a history of consuming milk products produced by dairy A during the 6 weeks preceding illness and for whom a bacterial isolate was not available for PFGE analysis.
Five patients had illness consistent with the case definition (Table) . All but patient 2 met the first case definition criterion; patient 2 met the second criterion. The median age of patients was 75 years (range: 31-87 years); three were male. All five patients were hospitalized. All three of the males (aged 75-87 years) died; they each had sepsis attributed to Listeria and died close to the time of their acute illness onset. The first case in a female was in a woman aged 31 years (patient 2) who had chorioamnionitis at 36 weeks' gestation. She delivered a healthy but premature infant. A placental culture was positive for L. monocytogenes. The second case in a female was in a woman aged 34 years (patient 4) who had fever and abdominal pain. She experienced a stillbirth at 37 weeks' gestation, and cultures of her blood, fetal blood, and placental tissue all were positive for L. monocytogenes.
Interviews were conducted with patients or patients' families using the CDC extended Listeria questionnaire. Patient 4 could not be interviewed. Of the remaining four patients, all but patient 3 were documented to have consumed products from dairy A during the 6 weeks preceding their illness. Patient 1 regularly consumed home-delivered, pasteurized skim milk produced by dairy A. Patient 2 reported drinking pasteurized 2% and whole milk produced by dairy A throughout her pregnancy. Patient 5 reported consuming pasteurized, coffeeflavored milk produced by dairy A.
Environmental Investigation
On December 17, evidence of Listeria growth was reported from the coffee-flavored milk sample from the home of patient 5. On December 21, this organism was confirmed to be L. monocytogenes and matched the four clinical isolates by PFGE using the two restriction enzymes. The Massachusetts Food Protection Program (MFPP) inspected dairy A and collected 11 samples of unopened, flavored and unflavored milk products for testing on December 18, in response to the findings on December 17.
MFPP returned to dairy A on December 26 and collected environmental swab samples from inside the processing facil * A case of outbreak-associated listeriosis was defined as illness in a Massachusetts resident with illness onset in 2007 who 1) was culture-positive for L. monocytogenes with pulsed-field gel electrophoresis (PFGE) patterns that matched the outbreak patterns generated with AscI and ApaI restriction enzymes or 2) had culture-confirmed L. monocytogenes and a history of consuming milk products produced by dairy A during the 6 weeks preceding illness and for whom a bacterial isolate was not available for PFGE analysis.
PFGE and other systems for genotyping L. monocytogenes isolates from clinical specimens can discriminate single-source clusters of foodborne infection (5, 6) and can contribute to the identification and investigation of outbreaks (7, 8) . The outbreak described in this report probably would not have been identified without molecular typing.
Although the effectiveness of PulseNet is well-documented (9), it is entirely dependent upon the consistent and timely submission of all isolates from clinical laboratories to public health laboratories. In Massachusetts, before this outbreak, submission of all L. monocytogenes isolates from clinical specimens by clinical laboratories was strongly encouraged but not required. On July 25, 2008, amendments to Massachusetts regulations* went into effect that require clinical laboratories to submit all clinical isolates of L. monocytogenes to SLI for PFGE analysis.
The findings from this outbreak underscore the importance of physical facility and equipment design and crosscontamination controls, particularly in older facilities that manufacture perishable, ready-to-eat foods that have a long shelf-life and that support the growth of L. monocytogenes under refrigeration. Three new vaccines have been recommended for adolescents by the Advisory Committee for Immunization Practices (ACIP) since 2005: meningococcal conjugate vaccine (MCV4; 1 dose), tetanus, diphtheria, acellular pertussis vaccine (Tdap; 1 dose), and quadrivalent human papillomavirus vaccine (HPV4; 3 doses)* (1). ACIP also recommends that adolescents should receive recommended vaccinations that were missed during childhood (1). Since 2006, CDC has conducted the National Immunization Survey-Teen (NIS-Teen) to estimate vaccination coverage from a national sample of adolescents aged 13-17 years. This report describes the findings from NIS-Teen 2007, which indicated substantial increases in receipt of new adolescent vaccinations compared with 2006, including Tdap (from 10.8% to 30.4%) and MCV4 (from 11.7% to 32.4%), and increases in coverage with childhood vaccinations, including measles, mumps, and rubella (MMR), hepatitis B (HepB), and varicella (VAR) (among those without disease history). An assessment of HPV4 coverage, which is reported for the first time, showed that 25.1% of adolescent females initiated the vaccine series (>1 dose) in 2007. To improve vaccination coverage among adolescents, health-care providers should take advantage of every health-care visit as an opportunity to evaluate vaccination status and administer vaccines when needed.
NIS-Teen collects vaccination information on age-eligible adolescents aged 13-17 years using a random-digit-dialing sample of telephone numbers of households. After parent/ guardian respondents grant permission, surveys are mailed to the adolescents' vaccination providers to obtain vaccination histories (2) . During the fourth quarter of 2007, among households identified by telephone, 81.5% were screened for an ageeligible adolescent. † Among the 9.5% in which an age-eligible adolescent lived, 83.3% (5,474) completed the household interview. Provider-reported vaccination records were obtained from 2,947 adolescents, representing 53.8% of adolescents with completed household interviews. Statistical analyses were conducted using chi-square and t-tests. Differences were considered statistically significant at p<0.05.
Among adolescents aged 13-17 years, vaccination coverage with ≥1 dose of either tetanus and diphtheria toxoids vaccine (Td) or Tdap after age 10 years was 72.3%, a significant increase from the 60.1% coverage rate measured in 2006 (p<0.05) (Table) Editorial Note: This is the second report of national adolescent vaccination coverage estimates based on provider-reported (1) . However, some younger adolescents still received Td; further study is needed to assess this finding. Older adolescents likely received Td because they were vaccinated before Tdap became available in 2005. These adolescents should now receive Tdap. Although ACIP recommends a 5-year interval between Td and Tdap, the interval can be shorter in circumstances where pertussis is circulating in the community or the risk for pertussis is high (5) .
This report provides the first coverage estimates for HPV4 since the ACIP recommendations were published in March 2007. Routine vaccination with HPV4 is recommended for females at age 11-12 years (1) . Approximately 25% of females aged 13-17 years had initiated the HPV4 series, with no observed differences among age groups. This finding is of particular interest because studies conducted before vaccine licensure suggested that providers preferred to vaccinate older adolescent females (6) . Only a quarter of HPV4 vaccination recipients had completed the 3-dose series. However, because at least 6 months is required to complete the series, some respondents who received the first dose might not have had sufficient time to complete the series by the survey interview date. Vaccine series completion will be monitored in future surveys, and the results will be used to refine strategies to promote completion of the series.
As For the past 10 years, professional organizations have recommended a preteen health-care visit at age 11-12 years for delivery of preventive services, including vaccinations (8) . The adolescent vaccination schedule consists of both new vaccinations recommended specifically during adolescence and vaccinations recommended during early childhood that might have been missed. Optimally, adolescent vaccines should be delivered during the age 11-12 year health-care visit. Vaccinations not received at that time should be administered at the earliest opportunity. Because adolescents make few preventive health-care visits and might not visit their primary care provider routinely (8) , each health-care encounter becomes an opportunity to review vaccination records and administer recommended vaccinations. Strategies to improve vaccination coverage include simultaneously administering needed vaccinations at the same visit and setting up systems to remind parents when vaccines for their adolescent are due or have been missed (9) . The findings in this report are subject to at least three limitations. First, NIS-Teen is a telephone survey and some bias might remain after adjustments for nonresponse and for noninclusion of households without landline telephones. However, data from the 2006 National Health Interview Survey show that this bias is minimal; only 7.5% of adolescents were reported living in cellular-only households and 2.1% were reported having no telephone service (10) . Second, NIS-Teen uses provider-reported vaccination histories, and the generalizability of the survey depends on the assumption that coverage among adolescents for whom adequate provider data were not available is similar to coverage among adolescents for whom adequate provider data were available, after controlling for factors associated with vaccine coverage. If this assumption is not correct, an underestimation or overestimation of vaccination coverage might have resulted. Finally, some provider-reported vaccination histories also might not have included all vaccinations received (e.g., vaccinations given in nontraditional settings such as emergency departments), which also might have resulted in underestimated coverage.
Vaccination coverage among adolescents will continue to be monitored annually. In 2008, NIS-Teen is collecting state and local data that will provide a larger sample size adequate for examining vaccination coverage by race/ethnicity, socioeconomic status, and geographic area. 
Updated Recommendations for Isolation of Persons with Mumps
Mumps, an acute vaccine-preventable viral illness transmitted by respiratory droplets and saliva, has an incubation period most commonly of 16-18 days. The classic clinical presentation of mumps is parotitis, which can be preceded by several days of nonspecific prodromal symptoms; however, mumps also can be asymptomatic, especially in young children. Mumps transmission can occur from persons with subclinical or clinical infections and during the prodromal or symptomatic phases of illness (1, 2) . In 2006, during a mumps resurgence in the United States, the latest national recommendations from CDC and the American Academy of Pediatrics (AAP) stipulated that persons with mumps be maintained in isolation with standard precautions and droplet precautions for 9 days after onset of parotitis (3).* However, the existence of conflicting guidance (i.e., that the infectious period of mumps extended through the fourth day after parotitis onset † ) led to confusion regarding the appropriate length of isolation. In addition, during the 2006 resurgence, compliance with recommendations for isolation in university settings was substantially lower for 9 days (65%) compared with 4-5 days (86%) (4). In 2007, after a review of the evidence supporting the 9-day isolation guidance by AAP and CDC, AAP changed its isolation guidance for health-care workers in ambulatory settings from 9 days to 5 days (5). In February 2008, after review of data on mumps in health-care settings, mumps viral load, and mumps virus isolation, the Healthcare Infection Control Practices Advisory Committee (HICPAC) approved changes in its recommendations related to mumps in in-patient settings. As a result, CDC, AAP, and HICPAC all now recommend a 5-day period after onset of parotitis, both for isolation of persons with mumps in either community or health-care settings and for use of standard precautions and droplet precautions. This report summarizes the scientific basis for these changes in mumps isolation guidance.
To review the scientific evidence underlying the 9-day isolation recommendation, researchers from CDC and AAP searched available literature for relevant published articles * Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00053391.htm. † Available at http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mumps. pdf.
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on mumps transmission and mumps in health-care settings. Because existing data on mumps transmission are scant, the literature review included reports on factors that are considered to be correlated with mumps transmission risk, including articles on viral isolation and viral load from saliva or respiratory secretions. Data on viral isolation from saliva or throat swabs were available from eight small studies (median number of subjects: 16; range 1-46). Seven studies were conducted before the availability of mumps vaccine or in countries without a mumps vaccination program; the eighth study was conducted in the postvaccine era in a community with low vaccination coverage, and the vaccination status of the mumps patients was not stated. Among the eight studies, although mumps virus was isolated successfully from 7 days before (6) to 8 days after (7) onset of parotitis, isolation rates were much greater closer to parotitis onset. For seven of the eight studies with available data on isolation of mumps virus by day relative to onset of parotitis, combined data showed that the proportion of samples positive for mumps virus increased from 17% (one of six specimens) 6-7 days before onset of parotitis to 40% (four of 10 specimens) 2-3 days before onset, 86% (six of seven specimens) 1 day before onset, and 78% (seven of nine specimens) on the day of parotitis onset. The data also showed that the proportion of samples positive for mumps virus decreased from 81% (29 of 36 specimens) 1 day after parotitis onset to 49% (18 of 37 specimens) 2-3 days after onset, 40% (six of 15 specimens) 4-5 days after onset, and 17% (one of six specimens) 6-7 days after onset of parotitis. In the eighth study, viral identification using reverse transcription-polymerase chain reaction from buccal specimens from patients with parotitis was conducted during the 2006 mumps outbreak at a U.S. college where most patients had been vaccinated with 2 doses of measles, mumps, and rubella (MMR) vaccine. The study found that, among 20 patients tested <3 days after onset of parotitis, mumps viral RNA was detected in seven (35%) (8) . A total of 26 specimens from 14 patients tested from 4-22 days after onset of parotitis all were negative for mumps viral RNA. A study from Japan, examining viral load during the course of natural infection, found that viral load decreased substantially during the first 4 days after illness onset and was extremely low thereafter (9) .
Serious consequences of mumps transmission in health-care settings are rare. This is likely explained by the relatively low infectiousness and transmission rate of mumps and the fact that hospitalization for mumps is uncommon. Although mumps transmission from patients to health-care personnel (HCP) in emergency departments occurred during the 1986-1987 mumps outbreaks in Tennessee, most mumps cases among HCP during that period were believed to be acquired in the community (10) . Mumps transmission also has occurred in hospital settings despite prompt isolation of cases after onset of parotitis, affirming other research indicating that viral shedding occurs before onset of parotitis (1) .
The scientific evidence from the CDC and AAP review indicates that, although mumps virus can be isolated from saliva or respiratory secretions 5 or more days after parotitis onset, virus most often is isolated before or around the time of onset, and viral load decreases rapidly during the 4 days after onset of parotitis. Therefore, the risk for transmission after 5 days is considered low; most transmission likely occurs before onset of parotitis and within the subsequent 5 days. Transmission also occurs from persons with subclinical infections who are not isolated. A longer isolation period of 9 days likely would result in less compliance and more cost and not produce any substantial decrease in mumps transmission.
Based on this review, CDC, AAP, and HICPAC now recommend a 5-day period after onset of parotitis for 1) isolation of persons with mumps in either community or health-care settings and 2) use of standard precautions and droplet precautions. Postexposure recommendations remain unchanged. HCP with no evidence of mumps immunity who are exposed to patients with mumps should be excluded from duty from the 12th day after first exposure through the 26th day after last exposure.
The best strategy for preventing mumps in the community and among HCP is promoting high levels of immunity by vaccination. A 2-dose regimen is currently recommended for all children, with the first MMR vaccine dose administered at 12-15 months and the second at 4-6 years. Unless they have other evidence of mumps immunity, § all school-aged children, students in post high school institutions (e.g., colleges), international travelers, and HCP also should receive 2 doses of MMR vaccine. Other adults should receive at least 1 dose of MMR vaccine. ¶ Other methods for decreasing transmission in the community and health-care settings include 1) isolation of cases, 2) postexposure exclusion from duty of HCP without evidence of immunity, and 3) use of standard precautions (including respiratory hygiene and cough etiquette) and transmission-based droplet precautions while caring for patients with mumps.
Notice to Readers

National Latino AIDS Awareness DayOctober 15, 2008
October 15 is National Latino AIDS Awareness Day (NLAAD), which seeks to increase awareness of the disproportionate effects of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) in the Hispanic/ Latino population living in the United States. In 2006, Hispanics accounted for approximately 14.8% of the U.S. population but 18.4% of persons who received an HIV/AIDS diagnosis (1). For 2006, estimates of HIV incidence show that blacks had the highest rate of new infections (83.8 per 100,000 population), followed by Hispanics (29.4 per 100,000) and non-Hispanic whites (11.5 per 100,000) (2 Table 3 . In the row titled, "Extra embryo(s) available and cryopreserved," the values for "Yes" and "No," should be transposed.
Errors also occurred on page 18 in Table 4 . In the row titled, "Extra embryos available and cryopreserved," the values for "Yes" and "No," should be transposed; in the row titled, "Use of gestational carrier," the values for "Yes" and "No," should be transposed. § Based on responses to numerous questions, which can be found in the appendix of the source publication. Any complex activity limitation is a combination measure that represents restrictions in any specific tasks or activities, including personal care, attending school, keeping house, or working. Movement difficulty is difficulty with at least one of eight basic areas of physical functioning because of a health problem and without using special equipment.
Erratum
Emotional difficulty represents problems with emotional functioning and is based on a score of 13 or more on the K6 serious psychological distress scale. Seeing or hearing difficulty represents difficulty with sensory functioning such as vision problems, even when wearing eyeglasses, or being unable to see at all, or having trouble hearing without a hearing aid or being deaf. Cognitive difficulty represents cognitive functioning difficulties in the areas of remembering or experiencing periods of confusion. ¶ 95% confidence interval.
During 2001-2005, the prevalence of obesity was greater among adults with movement (33%), emotional (33%), seeing or hearing (27%), or cognitive (27%) difficulties and among those with any complex activity limitation (32%) than among adults with no disabilities (19%). -0  3  25  43  Hawaii  -1  6  35  63  -12  22  441  507  -0  2  15  9  Oregon  §  6  9  19  349  346  -23  63  939  906  -1  4  45  48  Washington  17  9  87  298  356  22  61  97  2,369  2,928  -0  3  3  2  American Samoa  -0  0  ---0  1  3 Rico  2  2  13  103  319  2  5  25  215  256  -0 Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). 1  2  7  94  107  -1  7  50  97  2  3  14  101  115  Connecticut  1  0  4  25  16  -0  7  19  31  2  0  5  32  30  Maine  §  -0  2  6  3  -0  2  10  10  -0  2  7  4  Massachusetts  -1  5  38  56  -0  3  9  36  -0  3  13  32  New Hampshire  -0  2  12  12  -0  1  6  4  -0  5  24  7  Rhode Island  §  -0  2  11  12  -0  2  4 9  7  15  282  385  13  15  60  603  795  9  8  28  320  315  Delaware  -0  1  6  7  -0  3  7  14  -0  2  10  9  District of Columbia  U  0  0  U  U  U  0  0  U  U  -0  1  11  12  Florida  4  3  8  119  119  9  6  12  259  261  5  3  7  118  115  Georgia  1  1  4  36  55  4  3  7  102  122  -0  3  21  28  Maryland  §  1  0  3  13  62  -0  4  17  93  -1  10  69  58  North Carolina  3  0  9  55  48  -0  17  62  107  4  0  7  28  35  South Carolina  §  -0  2  11  15  -1  6  44  52  -0  2  10  14  Virginia  §  -1  5  38  71  -2  16  77  108  -1  6  39  36  West Virginia  -0  2  4  8  -1  30  35  38  -0  3  14  8  E.S. Central  -1  9  64  89  -7  13  274  296  -2  10  91  76  Alabama  §  -0  4  9  17  -2  5  84  102  -0  2  12  9  Kentucky  -0  3  24  18  -2  5  70  56  -1  4  45  39  Mississippi  -0  2  4  8  -0  3  31  31  -0  1  1  -Tennessee  §  -0  6  27  46  -2  8  89  107  -1  5  33  28  W.S. Central  -5  55  186  192  -15  131  494  676  -1  23  57  99  Arkansas  §  -0  1  5  11  -1  4  30  60  -0  2  9  12  Louisiana  -0  1  10  26  -2  4  61  79  -0  2  8  4  Oklahoma  -0  3  7  10  -2  37  84  48  -0  3  3  5  Texas  §  -5  53  164  145  -9  107  319  489  -1  18  37  78  Mountain  1  4  9  150  189  1  4  10  149  163  1  2  5  56  84  Arizona  1  2  8  66  128  -1  5  49  69  -0  5  14  31  Colorado  -1  3  32  21  1  0  3  23  25  1  0  1  6  19  Idaho  §  -0  3  17  4  -0  2  6  11  -0  1  3  5  Montana  §  -0  1  1  9  -0  1  2  --0  1  3  3  Nevada  §  -0  2  5  10  -1  3  30  36  -0  1  8  8  New Mexico  §  -0  3  15  9  -0  2  9  11  -0  1  4  9  Utah  -0  2  11  6  -0  5  27  7  -0  3  18  6  Wyoming  §  -0  1  3  2  -0  1  3  4  -0  0  -3  Pacific  7  10  51  440  521  7  8  30  293  397  5  4  18  177  93  Alaska  -0  1  2  3  -0  2  9  4  -0  1  1  -California  6  8  42  359  453  5  5  19  207  295  5  3  14  140  69  Hawaii  -0  2  14  5  -0  2  6  11  -0  1  5  1  Oregon  §  -0  3  23  22  -1  3  34  46  -0  2  15  8  Washington  1  1  7  42  38  2  1  9  37  41  -0  3  16  15  American Samoa  -0 Table I . § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). -2  11  69  61  -1  64  57  74  -2  13  87  86  Arkansas  §  -0  1  2  1  -0  1  ---0  2  7  9  Louisiana  -0  1  2  2  -0  1  2  14  -0  3  19  24  Oklahoma  -0  1  ---0  4  2  5  -0  5  12  15  Texas  §  -2  10  65  58  -1  60  53  55  -1  7  49  38  Mountain  -0  5  38  38  -1  3  25  54  -1  4  43  57  Arizona  -0  2  6  2  -0  2  11  11  -0  2  7  12  Colorado  -0  1  5  --0  2  4  21  -0  1  10  20  Idaho  §  -0  2  8  7  -0  1  1  2  -0  2 -0  91  6  45  25  -0  14  44  80  Louisiana  -1  5  54  16  -0  0  -6  -0  1  3  4  Oklahoma  -0  26  32  6  -0  32  32  45  -0  132  142  45  Texas  †  -17  179  865  681  -0  27  2  801  -1  8  30  33  Mountain  4  17  37  625  842  -1  5  61  76  -0  3  27  31  Arizona  2  3  10  156  184  N  0  0  N  N  -0  2  10  7  Colorado  2  3  13  118  236  -0  0  ---0  1  1  3  Idaho  †  -0  4  22  37  -0  1  -9  -0  1  1  4  Montana  †  -1  11  74  36  -0  2  8  16  -0  1  3  1  Nevada  †  -0  7  24  34  -0  2  7  10  -0  1  1  -New Mexico  †  -0  5  30  64  -0  3  24  10  -0  1  2  4  Utah  -6  27  188  231  -0  3  7  13  -0  0  --Wyoming  †  -0  2  13  20  -0  3  15  18  -0  2  9  12  Pacific  7  20  303  859  694  6  4  12  155  194  -0  1  4  3  Alaska  -2  29  140  45  -0  4  12  38  N  0  0  N  N  California  -7  129  257  363  5  3  12  135  146  -0  1  1  1  Hawaii  -0  2  10  18  -0  0  --N  0  0  N  N  Oregon  †  1  3  8  140  98  1  0  1  8  10  -0  1  3  2  Washington  6  6  169  312  170  -0 -0  2  5  17  -0  2  5  11  Louisiana  -0  2  12  14  -0  2  10  30  Oklahoma  1  2  19  93  58  3  1  7  55  39  Texas  §  -6  65  254  164  1  3  58  132  102  Mountain  7  11  22  443  465  -5  12  180  176  Arizona  2  3  9  160  181  -2  8  91  87  Colorado  5  2  8  127  114  -1  4  51  37  Idaho  §  -0  2  11  15  -0  1 -0  2  12  5  -0  1  3  2  5  2  19  121  94  Louisiana  -1  7  51  60  -0  2  9  5  14  10  22  372  388  Oklahoma  N  0  0  N  N  N  0  0  N  N  -1  5  54  52  Texas  §  -0  0  ---0  0  ---23  47  985  876  Mountain  -1  7  26  47  -0  2  4  12  -9  29  319  364  Arizona  -0  0  ---0  0  ---5  21  145  194  Colorado  -0  0  ---0  0  ---2  7  78  38  Idaho ---------------Guam  -0  0  ---0  0  ---0  0  --Puerto Rico  -0  0  ---0  0  --3  3  11  122 -11  38  469  607  -0  2  8  12  -0  1  -6  Louisiana  -1  10  61  99  -0  3  9  24  -0  6  27  11  Oklahoma  N  0  0  N  N  -0  2  3  57  -0  3  6  45  Texas  ¶  27  166  852  5,917  7,417  -0  10  33  149  -0  6  18  76  Mountain  7  40  105  1,464  2,028  -0  11  64  276  -0  22  150  1,029  Arizona  -0  0  ---0  9  37  42  -0  4  20  40  Colorado  7  14  43  658  845  -0  4  13  98  -0  12  64  476  Idaho  ¶  N  0  0  N  N  -0  1  2  11  -0  7  30  118  Montana  ¶  -5  27  223  301  -0  1  -36  -0  2  5  165  Nevada  ¶  N  0  0  N  N  -0  2  8  1  -0  3  7  10  New Mexico  ¶  -4  22  165  310  -0  1  3  38  -0  1  1  21  Utah  -10  55  408  548  -0  1  1  27  -0  3  15  41  Wyoming  ¶  -0  9  10  24  -0  0  -23  -0  2  8  158  Pacific  -1  7  64  55  3  0  33  190  157  1  0  17  111  240  Alaska  -1  5  50  29  -0  0  ---0  0  --California  -0  0  --3  0  33  189  150  1  0  16  106  221  Hawaii  -0  6 ---------------Guam  -2  17  55  218  -0  0  ---0 
